.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent findings highlight the significant First-Tier Exome Sequencing Utility for managing children with suspected rare genetic diseases. Specifically, a simulation of 523 patients showed that starting with exome sequencing (ES) improves clinical outcomes. Researchers used 'post-exome testing decision change' (P-TDC) to measure how ES results influence diagnostic pathways. This metric effectively quantifies the tests physicians order or avoid based on genomic data.
The study found a high P-TDC of 0.94 for first-tier ES. In addition, delayed testing reduced this clinical utility score to just 0.71. Early sequencing also proved most economical, costing approximately $3,414 per patient. Conversely, delayed strategies increased healthcare costs to over $10,026. Therefore, first-tier ES provides a consistent diagnostic yield while accelerating targeted treatment pathways for families.
Late testing extended the time to diagnosis by over three years in many cases. This delay often results in a costly and exhausting diagnostic odyssey. However, early implementation helps doctors bypass expensive and unnecessary investigations. Consequently, many international clinical guidelines now support genomic sequencing as a primary tool for pediatric rare diseases.
Post-exome testing decision change (P-TDC) measures clinical utility by quantifying how exome sequencing results influence the physician's decision to order or avoid further diagnostic tests.
By providing a diagnosis earlier, it avoids a lengthy and expensive \"diagnostic odyssey\" involving multiple lower-yield tests, thereby reducing overall healthcare expenditure.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and is not intended to replace professional judgment in diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Tagimacruz T et al. Clinical Utility of Exome Sequencing: Post-Exome Testing Decision Changes in the Management of Children with Suspected Rare Genetic Disease. Genet Med. 2026 Jun 10. doi: undefined. PMID: 42273873.
American Academy of Pediatrics. Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay. Pediatrics. 2024.
Makol A et al. Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases. Genet Med. 2021;23(11):2095-2104.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent study highlights the clinical utility of first-tier exome sequencing in pediatric rare diseases. Early testing achieved a 0.94 decision-change rate, reduced diagnostic time by over 3 years, and lowered costs to $3,414, proving more effective than delayed diagnostic strategies.
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
